This post-hoc analysis of the EVEREST ( Efficacy of Vasopressin Antagonism in Heart Failure : Outcome Study With Tolvaptan ) trial examined 1,947 patients with HHF and EF40 % not in atrial fibrillation/flutter or pacemaker dependent .